Working... Menu
Trial record 35 of 165 for:    Recruiting, Not yet recruiting, Available Studies | Osteoporosis

Percutaneous Vertebroplasty Versus Conservative Treatment in GIOPVCF

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03330340
Recruitment Status : Not yet recruiting
First Posted : November 6, 2017
Last Update Posted : November 6, 2017
Information provided by (Responsible Party):
Haolin Sun, Peking University First Hospital

Brief Summary:

Based on the case reports and other literature, the investigators hypothesize that using PVP for treating GIOPVCF is associated with increased risk of vertebral refractures and does not provide further benefits compared to conservative treatments.

The overall objective of this prospective cohort study is to compare the efficacy of PVP and conservative treatment for GIOPVCF. The evaluation of efficacy of therapy includes: 1) the incidence of vertebral refractures; 2) therapeutic effects (pain relief and health-related life quality) and 3) complications.

The results from study will be written in English and disseminated widely through scholarly presentations, peer-reviewed publications, and other written communications.

Condition or disease Intervention/treatment
Osteoporosis Procedure: Percutaneous Vertebroplasty

Detailed Description:

Patient recruitment and informed consent The study will recruit patients with GIOPVCF after consultation with inpatients and outpatients. The principal investigator of the study will screen the clinical information and inform the patients whether they are eligible for the study. After explaining the two therapeutic strategies (conservative treatment and PVP) and signing the informed consent, the patients will be divided into conservative treatment or PVP group based on their own decision.

The general information and medicine history of the participants are collected: age, gender, original disease, the course of original disease, specific GCs that have been used, the dosage/length of the GCs treatment, specific anti-osteoporosis medicine have been used and the dosage and length of usage. The bone density of the patient will then be evaluated using Dual-energy X-ray absorptiometry (DXA).

Withdrawal of individual subject Patients can withdraw from the study at any time for any reason without any consequences. The investigator can also decide to release patients from the study for medical reasons. For every patient who decides to withdraw from the study, the reasons of withdrawal will be recorded.

Sample size calculation A p-value is less than significance level (α) of 0.05 is considered as statistically significant. The statistical power (1-β) is defined as 80%. Based on the survival analysis of primary endpoint , the incidence of refracture in the patients with GIOPVCF is 48.6% after initial PVP operation and 17% after initial conservative treatment. Thus, power analysis indicates the study requires 42 patients per group to achieve statistical significance between two groups. Considering 20% of patients may be lost during follow-up visits, the investigators will recruit 53 patients for each group.

Statistical analysis Standard statistical techniques will be used to describe characteristics of patients in both groups. The investigators will compare baseline characteristics in the two treatment groups and if incomparability appears, the investigators will in secondary analysis adjust for differences. The incidence of vertebral refracture between groups will be compared with the Kaplan Meier survival analysis. Baseline differences of pain relief and health-related life quality between two groups will be assessed using student t test or nonparametric tests. Changes of VAS, ODI, and EQ-5D within the group from baseline to every follow-up time point will be compared using paired t test. A P value less than 0.05 is considered as statistically significant. SPSS 17.0 statistical program (SPSS, Chicago, IL) will be used for statistical analysis.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 106 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Percutaneous Vertebroplasty Versus Conservative Treatment in Vertebral Compression Fracture Associated With Glucocorticoids-induced Osteoporosis: a Prospective Cohort Study
Estimated Study Start Date : December 1, 2017
Estimated Primary Completion Date : December 30, 2019
Estimated Study Completion Date : December 30, 2019

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Percutaneous vertebroplasty
All PVPs are performed by experienced spine surgeons under optimal fluoroscopic guidance. The procedure takes place under sterile conditions. Local anesthesia is administered to the periosteum of the targeted pedicle via skin. Polymethylmethacrylate bone cement is injected under continuous fluoroscopic guidance using 1.0 ml syringes and 13 Gauge bone biopsy needles by bilateral procedures. Patients are encouraged to stand up and walk with brace immediately after operation and the brace are required to be worn for 3 months. Furthermore, all patients will take oral bisphosphonates treatment together with supplemental calcium and vitamin D.
Procedure: Percutaneous Vertebroplasty
The procedure takes place under sterile conditions. Local anesthesia is administered from skin to the periosteum of the targeted pedicle. Polymethylmethacrylate bone cement (Mendec Spine; Tecres SPA, Sommacampagna, Italy) is injected under continuous fluoroscopic imaging guidance using 1.0 ml syringes and 13 Gauge bone biopsy needles by bilateral procedures. The amount of injected cement in each treated vertebral body and any cement leakage is recorded.

Conservative treatment
In conservative treatment group, the patients were required horizontal bed rest for the initial 2 weeks after diagnosis. Then, they were encouraged to stand up and walk with brace and assistance. The bed rest time was extended if the back pain worsened when they stood up and walked. The brace should be worn in 3 months. For pain medication, nonsteroidal anti-inflammatory drugs (NSAIDs) were prescribed for every patient. Additional analgesics, such as tramadol and morphine, would be added in case NSAIDs were not effective. Two weeks after diagnosis, physical therapy was started. All patients are put on osteoporosis medication, bisphosphonates together with supplemental calcium and vitamin D.

Primary Outcome Measures :
  1. Incidence of vertebral re-fracture [ Time Frame: 12 months after the treatment ]
    Anterior-posterior and lateral spinal radiograph will be obtained. If a new vertebral fracture was doubted, MRI was undertaken to confirm it. When there is disagreement between both observers a consensus meeting is held. Incidence of vertebral re-fracture is Number of new fracture vertebrae/Number of total vertebrae

Secondary Outcome Measures :
  1. Visual Analog Scale (VAS) for back pain change from baseline to 12 months [ Time Frame: 12 months after the treatment ]
    All participants are asked to fill out standard questionnaires of the VAS score for back pain. The VAS pain is a single-item scale. For pain intensity, the scale is most commonly anchored by "no pain" (score of 0) and "pain as bad as it could be" or "worst imaginable pain" (score of 10). The change from baseline to 12-month post treatment will be compared between two groups

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients had fresh vertebral compression fractures with GIOP

Inclusion Criteria:

  1. Patients have fresh vertebral compression fractures regarding spine radiograph (minimum 15% height loss; level of fracture at Th5 or lower; bone edema on MRI, focal tenderness on VCF level).
  2. Patients have back pain for 6 weeks or less, with a visual analogue scale (VAS) score equal or less than 5.
  3. GCs consumption for more than 3 months (prednisone equivalent or more than 5 mg daily).
  4. Reduced bone density with T-scores equal or less than -1.
  5. Age at 55 or higher.


Exclusion Criteria:

  1. Concurrent other secondary osteoporosis.
  2. Previous PVP procedure or other spinal surgery on thoracic or lumbar segments.
  3. Systemic or local infection in spine (osteomyelitis, spondylodiscitis)
  4. Unable to comply with study due to severe psychosis.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03330340

Layout table for location contacts
Contact: Haolin Sun, Doctor +8613681146156

Sponsors and Collaborators
Peking University First Hospital
Layout table for investigator information
Study Director: Chunde Li, Doctor Peking University First Hospital

Layout table for additonal information
Responsible Party: Haolin Sun, Clinical Professor, Peking University First Hospital Identifier: NCT03330340     History of Changes
Other Study ID Numbers: HSun-1
First Posted: November 6, 2017    Key Record Dates
Last Update Posted: November 6, 2017
Last Verified: October 2017

Keywords provided by Haolin Sun, Peking University First Hospital:
vertebral compression fracture

Additional relevant MeSH terms:
Layout table for MeSH terms
Fractures, Compression
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Fractures, Bone
Wounds and Injuries
Polymethyl Methacrylate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Vasodilator Agents
Antimutagenic Agents
Protective Agents